The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in patients with high-risk DLBCL
Adrian Minson, MBBS, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia, gives an overview of the COALITION study (NCT04914741), which is evaluating the safety and efficacy of glofitamab plus R-CHOP or glofitamab plus polatuzumab vedotin-R-CHP (pola-R-CHP) in patients with high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL). Dr Minson first discusses the importance of developing improved treatment approaches for this high-risk patient population, and then gives an overview of the inclusion criteria and design of this trial. Following this, Dr Minson summarizes the main findings from the interim analysis of this trial, including the high overall response rates (ORR) observed, and concludes by discussing the safety profile of this combination. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding: Novartis, Roche, AbbVie
Travel funding: Novartis.
